|1.||Bell, P Darwin: 1 article (09/2014)|
|2.||Higashiyama, Shigeki: 1 article (09/2014)|
|3.||Dang, Yujing: 1 article (09/2014)|
|4.||Lemasters, John J: 1 article (09/2014)|
|5.||Abboud, Hanna E: 1 article (09/2014)|
|6.||Amria, May Y: 1 article (09/2014)|
|7.||Maldonado, Eduardo N: 1 article (09/2014)|
|8.||Beck Gooz, Monika: 1 article (09/2014)|
|9.||Mezil, Lynda: 1 article (01/2012)|
|10.||Berruyer-Pouyet, Carole: 1 article (01/2012)|
04/01/2011 - "Even though the dosage provided adequate exposure to inhibit TNF-α release, apratastat was not efficacious in rheumatoid arthritis (RA). "
11/01/2006 - "Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis."
01/01/2012 - "The thiomorpholine hydroxamate compound TMI-1 has been previously designed to inhibit metalloproteinase activity for the treatment of rheumatoid arthritis. "
11/01/2006 - "Wyeth Research was developing apratastat (TMI-005), one in a series of dual TNFalpha-converting enzyme and matrix metalloprotease-13 inhibitors, for the potential treatment of inflammation, especially rheumatoid arthritis. "
|3.||Cystic Kidney Diseases (Cystic Kidney Disease)
09/01/2014 - "Using Western blotting, an enzyme activity assay, and a growth factor-shedding assay in the presence or absence of the specific ADAM17 inhibitor TMI-005, we show that increased expression and activation of ADAM17 in the cystic kidney and in collecting duct epithelial cells originating from the Ift88°(rpk) mice (designated as PKD cells) lead to constitutive shedding of several growth factors, including heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, and transforming growth factor-α (TGF-α). "
|1.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|2.||Transforming Growth Factors (Transforming Growth Factor)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||heparin-binding EGF-like growth factor (HB-EGF)
|6.||amphiregulin (schwannoma-derived growth factor)